# Effectiveness of RSV Vaccines against RSV-Associated Thromboembolic Events

**Authors:** Ryan E. Wiegand, Heng-Ming Sung, Yue Zhang, Andrea Chavez, Amber Kautz, Josephine Mak, Morgan Najdowski, Yangping Chen, Yenlin Lai, Yixin Jiao, Yoganand Chillarige, Ruth Link-Gelles, Amanda B. Payne

PMC · DOI: 10.3201/eid3202.251520 · Emerging Infectious Diseases · 2026-02-01

## TL;DR

This study found that RSV vaccines are highly effective in preventing RSV-related blood clots in older adults.

## Contribution

The study provides new evidence on the effectiveness of RSV vaccines against thromboembolic events in elderly populations.

## Key findings

- RSV vaccines were 79% effective against RSV-associated thromboembolic events.
- Effectiveness was observed during the same season as vaccine receipt.

## Abstract

We evaluated effectiveness of respiratory syncytial virus (RSV) vaccines against RSV-associated thromboembolic events among community-dwelling Medicare fee-for-service beneficiaries >65 years of age in the United States enrolled during October 1, 2023–March 30, 2024. RSV vaccines protected against RSV-associated thromboembolic events (effectiveness 79% [95% CI 74%–83%]) in the same season as vaccine receipt.

## Full-text entities

- **Diseases:** Thromboembolic Events (MESH:D013923), venous thromboembolism (MESH:D054556), myocardial infarction (MESH:D009203), COVID-19 (MESH:D000086382), ischemic stroke (MESH:D002544), VE (MESH:D004673), influenza (MESH:D007251), respiratory syncytial virus (RSV) infections (MESH:D018357)
- **Species:** Respiratory syncytial virus (no rank) [taxon 12814], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12928231/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12928231/full.md

---
Source: https://tomesphere.com/paper/PMC12928231